Novel therapeutic approaches for inclusion body myositis

Current Opinion in Rheumatology

Volumn 22, Issue 6, 2010, Pages 658-664

  Lloyd, Thomas E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

autophagy; follistatin; inclusion body myositis; myostatin; regeneration; TDP 43; valosin containing protein

Indexed keywords

ACTIVIN RECEPTOR 2; AMYLOID BETA PROTEIN; ANDROGEN; ARIMOCLOMOL; BIOLOGICAL MARKER; CATHEPSIN B; CATHEPSIN D; CORTICOSTEROID; FOLLISTATIN; FOLLITROPIN; HEAT SHOCK PROTEIN; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METALLOPROTEINASE; MYO 029; MYOSTATIN; OXANDROLONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; PROTEIN KINASE B; RECOMBINANT FOLLISTATIN; RECOMBINANT PROTEIN; SMAD PROTEIN; SOLUBLE ACTIVIN RECEPTOR 2B; SOMATOMEDIN C; TAR DNA BINDING PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOSIN CONTAINING PROTEIN; VIRUS VECTOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOPHAGY; CELL PROLIFERATION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MARKER; DISULFIDE BOND; DRUG MEGADOSE; ENDOPLASMIC RETICULUM; FOLLITROPIN RELEASE; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; INCLUSION BODY MYOSITIS; INFLAMMATION; KNOCKOUT MOUSE; LOSS OF FUNCTION MUTATION; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE GROWTH; MUSCLE REGENERATION; MUSCULAR DYSTROPHY; NONHUMAN; PATHOGENESIS; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; RECEPTOR BINDING; REPRODUCTIVE TOXICITY; REVIEW; SKIN ALLERGY; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT; UPREGULATION;

DRUG DESIGN; HUMANS; MUSCLE FIBERS, SKELETAL; MYOSITIS, INCLUSION BODY; REGENERATION;

EID: 77958035689     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32833f0f4a     Document Type: Review

References (66)

1. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol 2010; 298:R1173-R1187.
2. Henriques-Pons A, Nagaraju K. Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis. Curr Opin Rheumatol 2009; 21:581-587.
3. Dalakas MC. Immunotherapy of myositis: issues, concerns and future pro-spects. Nat Rev Rheumatol 2010; 6:129-137.
4. Rutkove SB, Parker RA, Nardin RA, et al. A pilot randomized trial of oxan-drolone in inclusion body myositis. Neurology 2002; 58:1081-1087.
5. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997; 387:83-90.
6. Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004; 350:2682-2688.
7. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008; 63:561-571.
8. Cadena SM, Tomkinson KN, Monnell TE, et al. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fibertype. J Appl Physiol 2010 [Epub ahead of print].
9. Lee SJ, Reed LA, Davies MV, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 2005; 102:18117-18122.
10. Bogdanovich S, McNally EM, Khurana TS. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve 2008; 37:308-316.
11. Bartoli M, Poupiot J, Vulin A, et al. AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene Ther 2007; 14:733-740.
12. Rodino-Klapac LR, Haidet AM, Kota J, et al. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve2009; 39:283-296.
13. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001; 98:9306-9311.
14. Lee SJ. Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS One 2007; 2:e789.
15. Haidet AM, Rizo L, Handy C, et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci USA 2008; 105:4318-4322.
16. Kota J, Handy CR, Haidet AM, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med 2009; 1:6ra15.
17. Iezzi S, Di Padova M, Serra C, et al. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell 2004; 6:673-684.
18. Minetti GC, Colussi C, Adami R, et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 2006; 12:1147-1150.
19. Jones KL, Mansell A, Patella S, et al. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci USA 2007; 104:16239-16244.
20. Tedesco FS, Dellavalle A, Diaz-Manera J, et al. Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest 2010;120:11-19.
21. Yamanaka S. A fresh look at iPS cells. Cell 2009; 137:13-17.
22. Barberi T, Bradbury M, Dincer Z, et al. Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nat Med 2007; 13:642-648.
23. Darabi R, Gehlbach K, Bachoo RM, et al. Functional skeletal muscle regeneration from differentiating embryonic stem cells. Nat Med 2008; 14:134-143.
24. Sampaolesi M, Torrente Y, Innocenzi A, et al. Cell therapy of alpha-sarcogly-can null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 2003; 301:487-492.
25. Sampaolesi M, Blot S, D'Antona G, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006; 444:574-579.
26. Mammen AL, Casciola-Rosen LA, Hall JC, et al. Expression of the dermato-myositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum 2009; 60:3784-3793.
27. Karpati G, O'Ferrall EK. Sporadic inclusion body myositis: pathogenic con-siderations. Ann Neurol 2009; 65:7-11.
28. Temiz P, Weihl CC, Pestronk A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci 2009; 278:25-29.
29. Sugarman MC, Yamasaki TR, Oddo S, et al. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci USA 2002; 99:6334-6339.
30. Kitazawa M, Vasilevko V, Cribbs DH, et al. Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model. J Neurosci 2009; 29:6132-6141.
31. Greenberg SA. Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep 2010; 12:221-228.
32. Greenberg SA. How citation distortions create unfounded authority: analysis of a citation network. BMJ 2009; 339:b2680.
33. Kirkin V, McEwan DG, Novak I, et al. A role for ubiquitin in selective autophagy. Mol Cell 2009; 34:259-269.
34. Kieran D, Kalmar B, DickJR, et al. Treatment with arimoclomol, acoinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004; 10:402-405.
35. Lanka V, Wieland S, Barber J, et al. Arimoclomol: a potential therapy under development for ALS. Expert Opin Investig Drugs 2009; 18:1907-1918.
36. Cudkowicz ME, Shefner JM, Simpson E, et al. Arimoclomol at dosages up to 300mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve 2008; 38:837-844.
37. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132:27-42.
38. Garcia-Arencibia M, Hochfeld WE, Toh PP, et al. Autophagy, a guardian against neurodegeneration. Semin Cell Dev Biol 2010 [Epub ahead of print].
39. Kumamoto T, Ueyama H, Tsumura H, et al. Expression of lysosome-related proteins and genes in the skeletal muscles of inclusion body myositis. Acta Neuropathol 2004; 107:59-65.
40. Askanas V, Engel WK, Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multiprotein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol 2009; 19:493-506.
41. Komatsu M, Waguri S, ChibaT, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006; 441:880-884.
42. HaraT, Nakamura K, Matsui M, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006; 441:819-820.
43. Raben N, Hill V, Shea L, et al. Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease. Hum Mol Genet 2008; 17:3897-3908.
44. Masiero E, Agatea L, Mammucari C, et al. Autophagy is required to maintain muscle mass. Cell Metab 2009; 10:507-515.
45. Nogalska A, D'Agostino C, Terracciano C, et al. Impaired autophagy in sporadic inclusion-body myositisand in endoplasmic reticulum stress-provokedcultured human muscle fibers. Am J Pathol 2010; 177 [Epub ahead of print].
46. Nogalska A, Terracciano C, D'Agostino C, et al. p62/SQSTM1 is over-expressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it frompolymyositis and dermatomyositis. Acta Neuropathol 2009; 118:407-413.
47. Ramachandran N, Munteanu I, Wang P, et al. VMA21 deficiency causes an autophagic myopathy by compromising V-ATPase activity and lysosomal acidification. Cell 2009; 137:235-246.
48. Hirano M, DiMauro S. VMA21 deficiency: a case of myocyte indigestion. Cell 2009; 137:213-215.
49. Tresse E, Salomons FA, Vesa J, et al. VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD. Autophagy 2010; 6:217-227.
50. Ju JS, Fuentealba RA, Miller SE, et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol 2009;187:875-888.
51. Ju JS, Miller SE, Hanson PI, Weihl CC. Impaired protein aggregate handling and clearance underlie the pathogenesis of p97/VCP-associated disease. J Biol Chem 2008; 283:30289-30299.
52. Lee JY, Koga H, Kawaguchi Y, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 2010; 29:969-980.
53. Oldfors A, Moslemi AR, Jonasson L, et al. Mitochondrial abnormalities in inclusion-body myositis. Neurology 2006; 66:S49-S55.
54. Manfredi AA, Rovere-Querini P. The mitochondrion: a Trojan horse that kicks off inflammation? N Engl J Med 2010; 362:2132-2134.
55. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464:104-107.
56. Terracciano C, Nogalska A, Engel WK, Askanas V. In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J Neurochem 2010; 112:389-396.
57. Salih DA, Brunet A. FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr Opin Cell Biol 2008; 20:126-136.
58. Chen-Plotkin AS, Lee VM, Trojanowski JQ. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 2010; 6:211-220.
59. Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet2010; 19:R46-R64.
60. Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with fronto-temporal dementia. J Neurol Neurosurg Psychiatry 2008; 79:1186-1189.
61. Olive M, Janue A, Moreno D, et al. TAR DNA-binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 2009; 68:262-273.
62. Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009; 40:19-31.
63. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008; 319:1668-1672.
64. Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008; 40:572-574.
65. Ritson GP, Custer SK, Freibaum BD, et al. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97.J Neurosci 2010; 30:7729-7739.
66. Caccamo A, Majumder S, Deng JJ, et al. Rapamycin rescues TDP-43 mis-localization and the associated low molecular mass neurofilament instability.J Biol Chem 2009; 284:27416-27424.